[Advances in the Study of Invasive Non-mucinous Adenocarcinoma 
with Different Pathological Subtypes].

Ruke Tang(Kunming Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Bingquan Xiang(Kunming Medical University), Ying Chen(Shandong University of Traditional Chinese Medicine), Guangqiang Zhao(Kunming Medical University), Lina Bi(Kunming Medical University), Lianhua Ye(Kunming Medical University), Guangjian Li(Hohai University)
PubMed
January 20, 2023
10.3779/j.issn.1009-3419.2022.102.51
Cited by 1

Related Papers

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Lung Cancer|2018|134
<scp>C</scp>hina national lung cancer screening guideline with low‐dose computed tomography (2015 version)
|Thoracic Cancer|2015|89
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
|Journal of Clinical Oncology|2013|83